Pharma industry focuses on strategic investments amid reduced deal activity by 26.1 % compared to May 2023: GlobalData

hanuman

Active member
Screenshot-2024-06-07-145006.jpg


Merck, Biogen, and Novartis lead major transactions

In May 2024, the pharmaceutical industry strategically pursued key acquisitions and significant venture capital investments amidst a reduction in overall deal activity, while the healthcare sector witnessed a decline in transactions.

Despite this drop, three major transactions accounted for 51 per cent of the total deal value in May. Merck & Co Inc announced its acquisition of Eyebiotech for USD 3 billion, aiming to advance therapies for eye diseases. Biogen’s acquisition of Human Immunology Biosciences for approximately USD 1.8 billion aimed to strengthen its offerings in immune-mediated, allergic, and inflammatory disease therapeutics. Meanwhile, Novartis AG’s acquisition of Mariana Oncology Inc for an estimated USD 1.7 billion represented a strategic expansion into novel radioligand therapies for cancer treatment.

Image-2-report-GB.jpg




Venture capital investments decreased by 8.3 per cent in May 2024, compared to May 2023, 97 VC deals worth USD 3 billion reported in May 2024, compared to the previous 12-month average of 110 deals worth USD 2.7 billion.

AltruBio, a clinical stage biotechnology company dedicated to the development of novel therapeutics for the treatment of immunological diseases, raising USD 225 million in series B financing to advance the clinical development of novel immune checkpoint enhancer program; Zenas BioPharma (USA) , a biopharmaceutical company, raising USD 200 million in series C financing to advance mid and late-stage immunology-focused clinical development programs; TheRas, BridgeBio Oncology Therapeutics, raising USD 200M in financing to accelerate the development of its novel precision oncology pipeline. These were the three major VC deals reported in May 2024.



Image-4-report-GB.jpg


These trends highlight the pharmaceutical industry’s focus on strategic investments and acquisitions despite the overall downturn in deal activity, while the healthcare sector grapples with a decline in transactions. Companies are leveraging targeted funding strategies to drive innovation and address critical healthcare needs amidst industry changes.



The post appeared first on .
 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock